<< Read Full Article

Investors Display Allergic Reaction to Sepracor

 

Now that shares of Sepracor have been crushed because U.S. drug regulators rejected its highly anticipated allergy drug Soltara on Thursday, shell-shocked investors and analysts are trying to figure out whom to blame.

Is the Soltara fiasco the fault of a way-too-cautious Food and Drug Administration? Or has Sepracor been misleading investors all along about potential safety problems with its drug?

Shares of Sepracor plummeted $27.63, or 58%, on Thursday, closing at $19.64. ...

<< Read Full Article

Recent Comments

Loading .....




Dow Jones S&P 500 NASDAQ 10-Year Note
10,388.90 1,105.98 2,194.35 34.83
Oil *
77.74
UP
22.75
UP
6.06
UP
21.21
UP
1.03
10 Yr
3.48%
SPDR Gold
113.75
+0.22%
+0.55%
+0.98%
+3.05%
Data delayed 20 minutes

Brokerage Partners

TheStreet Premium Services

All Services